Cucurbitacin HCAS# 751-95-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 751-95-1 | SDF | Download SDF |
| PubChem ID | 441818 | Appearance | Powder |
| Formula | C30H46O8 | M.Wt | 534.7 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-17-[(2R)-2,5,6-trihydroxy-6-methyl-3-oxoheptan-2-yl]-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthrene-3,11-dione | ||
| SMILES | CC1(C2=CCC3C4(CC(C(C4(CC(=O)C3(C2CC(C1=O)O)C)C)C(C)(C(=O)CC(C(C)(C)O)O)O)O)C)C | ||
| Standard InChIKey | ABNDMUIXCBUBLO-REQJDAJISA-N | ||
| Standard InChI | InChI=1S/C30H46O8/c1-25(2)15-9-10-19-27(5)13-18(32)23(30(8,38)21(34)12-20(33)26(3,4)37)28(27,6)14-22(35)29(19,7)16(15)11-17(31)24(25)36/h9,16-20,23,31-33,37-38H,10-14H2,1-8H3/t16-,17+,18-,19+,20?,23+,27+,28-,29+,30+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Cucurbitacin H Dilution Calculator
Cucurbitacin H Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8702 mL | 9.351 mL | 18.7021 mL | 37.4042 mL | 46.7552 mL |
| 5 mM | 0.374 mL | 1.8702 mL | 3.7404 mL | 7.4808 mL | 9.351 mL |
| 10 mM | 0.187 mL | 0.9351 mL | 1.8702 mL | 3.7404 mL | 4.6755 mL |
| 50 mM | 0.0374 mL | 0.187 mL | 0.374 mL | 0.7481 mL | 0.9351 mL |
| 100 mM | 0.0187 mL | 0.0935 mL | 0.187 mL | 0.374 mL | 0.4676 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Cucurbitacin C
Catalog No.:BCN0916
CAS No.:5988-76-1
- Cinnamtannin D2
Catalog No.:BCN0915
CAS No.:97233-47-1
- Cinnamtannin D1
Catalog No.:BCN0914
CAS No.:97233-06-2
- Cinnamtannin B2
Catalog No.:BCN0913
CAS No.:88038-12-4
- Oenothein B
Catalog No.:BCN0912
CAS No.:104987-36-2
- Cinnamtannin A4
Catalog No.:BCN0911
CAS No.:88847-05-6
- 2-O-Acetylzeylenone
Catalog No.:BCN0910
CAS No.:358748-29-5
- Procyanidin B4 3'-O-gallate
Catalog No.:BCN0909
CAS No.:89064-33-5
- Procyanidin B2 3-O-gallate
Catalog No.:BCN0908
CAS No.:109280-47-9
- Procyanidin B1 3-O-gallate
Catalog No.:BCN0907
CAS No.:79907-45-2
- Leucocyanidin
Catalog No.:BCN0906
CAS No.:69256-15-1
- Peanut procyanidin F
Catalog No.:BCN0905
CAS No.:2095621-25-1
- Cucurbitacin F
Catalog No.:BCN0918
CAS No.:5939-57-1
- Cucurbitacin L
Catalog No.:BCN0919
CAS No.:1110-02-7
- Cucurbitacin P
Catalog No.:BCN0920
CAS No.:25383-26-0
- Cucurbitacin O
Catalog No.:BCN0921
CAS No.:25383-23-7
- Cucurbitacin K
Catalog No.:BCN0922
CAS No.:6766-43-4
- Cucurbitacin J
Catalog No.:BCN0923
CAS No.:5979-41-9
- 6-hydroxyapigenin-6-O-β-D-glucoside-7-O-β-D-glucuronide
Catalog No.:BCN0924
CAS No.:1146045-40-0
- Cistanoside B
Catalog No.:BCN0925
CAS No.:93236-41-0
- Purpureaside B
Catalog No.:BCN0926
CAS No.:104777-69-7
- Jionoside C
Catalog No.:BCN0927
CAS No.:120406-33-9
- Polygalasaponin B
Catalog No.:BCN0928
CAS No.:103444-92-4
- polygalasaponin Ⅰ
Catalog No.:BCN0929
CAS No.:162901-83-9
Plausible mechanisms explaining the role of cucurbitacins as potential therapeutic drugs against coronavirus 2019.[Pubmed:33251326]
Inform Med Unlocked. 2020;21:100484.
In the year 2019, the potent zoonotic virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to rage globally, which resulted in the World Health Organization (WHO) declaring it as a pandemic on March 11th, 2020. Although extensive research is currently ongoing worldwide to understand the molecular mechanism and disease pathogenicity of SARS-CoV-2, there are still many nuances to elucidate. Therefore, developing an appropriate vaccine or therapeutic drug to combat coronavirus 2019 (COVID-19) is exceedingly challenging. Such scenarios require multifaceted approaches to identify suitable contenders for drugs against COVID-19. In this context, investigating natural compounds found in food, spices, and beverages can lead to the discovery of lead molecules that could be repurposed to treat COVID-19. Sixteen cucurbitacin analogues were investigated for activity against the SARS-CoV-2 main protease protein (Mpro), angiotensin-converting enzyme 2 (ACE2) binding receptor, nonstructural protein 12 (NSP12) RNA-dependent RNA polymerase (RdRp), NSP13 helicase, and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway using several relevant tools and simulated screening methods. All key proteins were found to bind efficiently only with cucurbitacin G 2-glucoside and Cucurbitacin H with the lowest global energy. Further, the absorption, distribution, metabolism, and excretion (ADME) of all the cucurbitacins were analysed to explore their drug profiles. Cucurbitacin G 2-glucoside and H showed the best hits and all the analogues showed no adverse properties that would diminish their drug-likeness abilities. The encouraging results of the current study may lay the foundation for future research and development of effective measures and preventive medications against SARS-CoV-2.
